Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (6)

1

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer : An Open-Label, Single-Arm, Phase 2 Study

enthalten in: International journal of radiation oncology, biology, physics | 2023

von Peled, N. | Roisman, L. | Levison, E. | +22

CommentIn: Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):115-117. - PMID 37574235

2

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

enthalten in: The oncologist | 2022

von Moskovitz, M. | Dudnik, E. | Shamai, S. | +13

3

Novel and Promising Systemic Treatment Approaches in Mesothelioma

enthalten in: Current treatment options in oncology | 2021

von Dudnik, E. | Reinhorn, D. | Holtzman, L.

4

Height in adolescence as a risk factor for glioma subtypes : a nationwide retrospective cohort study of 2.2 million subjects

enthalten in: Neuro-oncology | 2021

von Tschernichovsky, R. | Katz, L. | Derazne, E. | +13

5

GLASS : Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Peled, N. | Gillis, R. | Kilickap, S. | +45

6

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer : Real-Life Clinical Experience

enthalten in: Targeted oncology | 2018

von Purim, O. | Beny, A. | Inbar, M. | +21

1
[1]